Compare Heron Therapeutics Inc (HRTX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 1239.7× Heron Therapeutics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| HRTX | MRSH | |
|---|---|---|
Market Cap | $68.01M | $84.31B |
Volume | 1,891,941 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $1.49 | $207.02 |
52-Week Low | $0.27 | $157.32 |
Typical Hold Time | 35 Days | 109 Days |
Enterprise Value | $174.75M | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Marsh (MRSH) trades at $176.67, up 1.73% today, near its consensus price target of $202.71. The stock shows a bullish technical trend with support at $174 and resistance at $178. Recent earnings beats and the acquisition of Accel Holdings highlight strong operational momentum. Revenue grew to $27.0B in 2025, with a net income margin of 14.24% and a P/E ratio of 21.57, indicating solid profitability amid moderate valuation.
The outlook remains positive with consistent earnings outperformance and strategic acquisitions driving growth. Risks include elevated debt levels and potential margin pressure. Analysts are mostly neutral (65% Hold), but the stock offers upside to the price target. Investors should weigh strong cash flow generation against macroeconomic sensitivities in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
